A 48-year-old woman with a BMI of 32 kg/m² presents with 3 months of irregular, heavy vaginal bleeding. She has not menstruated for 2 years prior to this episode. Pelvic examination is unremarkable. Haemoglobin is 10.2 g/dL. Pelvic ultrasound shows a normal uterus (endometrial thickness 8 mm), normal ovaries, and no focal lesions. Thyroid function and coagulation studies are normal. What is the most appropriate next step in management?

Explanation

## Clinical Context: Postmenopausal Bleeding This patient presents with **postmenopausal bleeding (PMB)** — vaginal bleeding occurring >12 months after the last menstrual period. This is a **red flag symptom** for endometrial pathology, including endometrial cancer. ### Risk Stratification **Key Point:** Although ultrasound shows normal endometrial thickness (8 mm), which is reassuring, the combination of: - Age 48 (perimenopausal/postmenopausal) - Obesity (BMI 32) — independent risk factor for endometrial cancer - Irregular, heavy bleeding after 2 years amenorrhoea - Return to bleeding after presumed menopause ...mandates **tissue diagnosis** to exclude endometrial malignancy. ### Why Hysteroscopy Is Indicated Here ```mermaid flowchart TD A[Postmenopausal bleeding]:::outcome --> B{Endometrial thickness<br/>on ultrasound}:::decision B -->|≤4 mm| C[Low risk; reassure]:::action B -->|5-8 mm| D{Age ≥45 or<br/>risk factors?}:::decision B -->|>8 mm| E[Hysteroscopy + biopsy]:::urgent D -->|Yes| F[Hysteroscopy + biopsy]:::action D -->|No| G[Observation or<br/>repeat ultrasound]:::action F --> H[Tissue diagnosis]:::outcome E --> H ``` **High-Yield:** The American College of Obstetricians and Gynaecologists (ACOG) and European guidelines recommend hysteroscopy with endometrial biopsy for: - All postmenopausal bleeding, regardless of ultrasound findings, **if the patient is symptomatic and willing** - Endometrial thickness 5–8 mm in high-risk patients (age >45, obesity, unopposed oestrogen, diabetes, hypertension) This patient meets criteria: age 48, obesity, and symptomatic bleeding. ### Differential Diagnosis of PMB | Cause | Frequency | Ultrasound Finding | Management | |-------|-----------|-------------------|-------------| | **Endometrial atrophy** | 60–80% | Thin endometrium (<4 mm) | Observation; HRT if symptomatic | | **Endometrial polyp** | 10–15% | Focal echogenic lesion | Hysteroscopic polypectomy | | **Endometrial hyperplasia** | 5–10% | Thickened endometrium (>8 mm) | Hysteroscopy + biopsy; progestin therapy | | **Endometrial cancer** | 5–10% | Variable; may be normal | **Hysteroscopy + biopsy (mandatory)** | | **Submucosal fibroid** | 5% | Focal lesion with vascularity | Hysteroscopic myomectomy | **Clinical Pearl:** Even with normal ultrasound (8 mm endometrium), endometrial cancer cannot be excluded in a symptomatic postmenopausal woman. Ultrasound has ~90% sensitivity for cancer, meaning ~10% of cancers are missed on imaging alone. ### Why NOT Medical Management First? **Warning:** Prescribing progestins, tranexamic acid, or hormonal contraceptives without tissue diagnosis in a postmenopausal woman is **dangerous**. These agents may mask or delay diagnosis of endometrial malignancy, allowing disease progression. - **Medroxyprogesterone:** Used for endometrial hyperplasia (after biopsy-confirmed diagnosis), not as first-line for PMB - **Tranexamic acid:** Reduces bleeding but does not address the underlying pathology; inappropriate without diagnosis - **Combined oral contraceptive:** Contraindicated in postmenopausal women; no role in PMB management **Key Point:** "Treat first, investigate later" is **never acceptable** in postmenopausal bleeding. Tissue diagnosis must precede treatment.